-
公开(公告)号：US20230348990A1
公开(公告)日：2023-11-02
申请号：US18016942
申请日：2021-07-20
Inventor： Melissa Tan , Robert Huddart , Anguraj Sadanandam , Gift Nyamundanda
IPC: C12Q1/6886
CPC classification number: C12Q1/6886 , C12Q2600/158 , C12Q2600/118 , C12Q2600/106
Abstract: The present invention provides a method for predicting the treatment response of a human bladder cancer patient, the method comprising: a) measuring the gene expression of at least 9, at least 10, at least 15, at least 20 or at least 30 of the genes from Group 1 in Table 10 and at least 1, at least 2, at least 3 or at least 5 of the genes from Groups 2-4 in Table 10 in a sample obtained from the bladder tumour of the patient to obtain a sample gene expression profile of at least said genes; and b) making a prediction of the treatment response and/or prognosis of the patient based on the sample gene expression profile. Related methods and systems are also described. The invention finds particular use in predicting whether a bladder cancer patient is likely to be sensitive to (chemo)radiation therapy.
-
公开(公告)号：US20230173048A1
公开(公告)日：2023-06-08
申请号：US17921837
申请日：2021-04-28
Inventor： Stephen Pettitt , Christopher Lord , Marco Punta , Alan Melcher
CPC classification number: A61K39/0011 , C12N15/902 , C12N15/86 , A61K35/17 , A61P35/00
Abstract: The present invention provides an anti-cancer vaccine comprising: (i) at least one peptide comprising the amino acid sequence of a neoantigen encoded by a mutant homologous recombination (HR) DNA repair gene selected from the group: BRCA1, BRCA2, PALB2, CDK12, RAD51B, RAD51C and RAD51D, wherein the mutant gene comprises a reversion mutation; and/or (ii) at least one polynucleotide encoding the at least one peptide of (i). Also provided are engineered T cells that recognise said neoantigen. Related methods and medical uses of the vaccine and/or engineered T cell are provided, including for the treatment of cancers, such as homologous recombination (HR) deficient cancers that acquire PARP inhibitor resistance or platinum resistance by development of reversion mutations in an HR DNA repair gene selected from the group: BRCA1, BRCA2, PALB2, CDK12, RAD51B, RAD51C and RAD51D.
-
公开(公告)号：US11517573B2
公开(公告)日：2022-12-06
申请号：US17470471
申请日：2021-09-09
Inventor： Udai Banerji
IPC: A61K31/506 , A61P35/04
Abstract: This invention relates to methods comprising administering a FAK inhibitor (e.g., VS-6063) in combination with a dual RAF/MEK inhibitor (e.g., CHS 126766) that are useful in the treatment of abnormal cell growth, such as cancer, in a subject such as humans.
-
公开(公告)号：US20220289757A1
公开(公告)日：2022-09-15
申请号：US17712541
申请日：2022-04-04
Inventor： Richard Marais , Caroline Springer , Dan Niculescu-Duvaz , Natalie Miller , Mohammed Aljarah , Alfonso Zambon , Leo Leung , Deborah Smithen , Michael Brown , Haoran Tang
IPC: C07D487/08 , A61P35/00
Abstract: This invention relates to compounds useful as lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family member (LOXL1, LOXL2, LOXL3, LOXL4) inhibitors. In addition there are contemplated pharmaceutical compositions comprising the compounds and the use of the compounds in the treatment of conditions mediated by LOX and LOXL, for example cancer. In particular a LOX inhibitor such as the present compounds may be for use in the treatment of a cancer associated with EGFR. The present invention also contemplates the identification of biomarkers that predict responsiveness to a LOX inhibitor.
-
公开(公告)号：US20220031698A1
公开(公告)日：2022-02-03
申请号：US17470471
申请日：2021-09-09
Inventor： Udai Banerji
IPC: A61K31/506 , A61P35/04
Abstract: This invention relates to methods comprising administering a FAK inhibitor (e.g., VS-6063) in combination with a dual RAF/MEK inhibitor (e.g., CHS 126766) that are useful in the treatment of abnormal cell growth, such as cancer, in a subject such as humans.
-
Patent Agency Ranking
公开(公告)号：US20220017516A1
公开(公告)日：2022-01-20
申请号：US17293970
申请日：2019-11-15
Inventor： Mohammed ALJARAH , Dan NICULESCU-DUVAZ , Leo LEUNG , Deborah SMITHEN , Michael BROWN , Lawrence Christopher DAVIES , Caroline SPRINGER
IPC: C07D471/08 , C07D487/08 , C07D295/088 , C07D487/04 , C07D239/48 , C07D295/108 , C07D487/10 , A61P35/00
Abstract: The disclosure relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, Formula (I) as defined herein. Compounds according to Formula I are pharmacologically effective as lysyl oxidase (LOX) inhibitors and are believed to be useful in the treatment of, for instance, cancer.
-
公开(公告)号：US11161839B2
公开(公告)日：2021-11-02
申请号：US16616906
申请日：2018-05-25
Applicant: Cancer Research Technology Limited , The Institute of Cancer Research: Royal Cancer Hospital
Inventor： Benjamin Richard Bellenie , Kwai Ming Jack Cheung , Owen Alexander Davis , Swen Hoelder , Rosemary Huckvale , Matthew Garth Lloyd
IPC: C07D413/14 , C07D401/14 , C07D471/04 , C07D471/10 , C07D491/10 , C07D405/14 , C07D401/12 , A61P35/00
Abstract: The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: Formula I wherein X1, X2, X3, R1, R2, R3, R4 and R5 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.
-
公开(公告)号：US20210163497A1
公开(公告)日：2021-06-03
申请号：US17046650
申请日：2019-04-12
Applicant: Cancer Research Technology Limited , The Institute of Cancer Research: Royal Cancer Hospital
Inventor： Benjamin Richard Bellenie , Kwai Ming Jack Cheung , Owen Alexander Davis , Swen Hoelder , Rosemary Huckvale , Gavin Collie , Mirco Meniconi , Alfie Brennan , Matthew Garth Lloyd
IPC: C07D498/04 , C07D498/20 , C07D513/04 , C07D519/00 , C07D498/14 , C07D471/04 , A61P35/00
Abstract: The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2, R30, R31 and Ring A are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.
-
公开(公告)号：US20210040078A1
公开(公告)日：2021-02-11
申请号：US16908487
申请日：2020-06-22
Inventor： Caroline SPRINGER , Richard MARAIS , Dan NICULESCU-DUVAZ , Leo LEUNG , Deborah SMITHEN , Cedric CALLENS , Haoran TANG
IPC: C07D417/12 , C07D333/34 , C07D277/36 , C07D263/46 , C07D409/12 , A61P35/00 , C07D277/26 , C07D333/18 , C12Q1/37
Abstract: Provided are compounds of the Formula (I), or a pharmaceutically acceptable salt thereof: wherein W, X, Y, Z, x, R1, R2, R3, x and n are defined in the specification. The compounds are inhibitors of lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family members (LOXL1, LOXL2, LOXL3, LOXL4) and are useful in therapy, particularly in the treatment of cancer. Also disclosed are LOX inhibitors for use in the treatment of a cancer associated with EGFR and biomarkers that predict responsiveness to a LOX inhibitor.
-
公开(公告)号：US20200331922A1
公开(公告)日：2020-10-22
申请号：US16755739
申请日：2018-10-12
Inventor： Richard Marais , Caroline Springer , Dan Niculescu-Duvaz , Natalie Miller , Mohammed Aljarah , Alfonso Zambon , Leo Leung , Deborah Smithen , Michael Brown , Haoran Tang
IPC: C07D487/08 , A61P35/00
Abstract: This invention relates to compounds useful as lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family member (LOXL1, LOXL2, LOXL3, LOXL4) inhibitors. In addition there are contemplated pharmaceutical compositions comprising the compounds and the use of the compounds in the treatment of conditions mediated by LOX and LOXL, for example cancer. In particular a LOX inhibitor such as the present compounds may be for use in the treatment of a cancer associated with EGFR. The present invention also contemplates the identification of biomarkers that predict responsiveness to a LOX inhibitor.
-
-
-
-
-
-
-
-
-
Search Results
69
records
(took 0.025 seconds)
